Anthony Hayes Buys 50,000 Shares of Dominari (NASDAQ:DOMH) Stock

Key Points

• CEO Anthony Hayes purchased 50,000 Dominari shares at an average price of $2.02, investing $101,000 and increasing his direct ownership by 1.11% to 4,550,873 shares.
• Dominari reported a quarterly loss of $0.21 per share, outperforming the $0.34 analyst consensus, while revenue reached $16.79 million. The stock opened at $2.18 and remains near its one-year low of $1.91.
• Analyst sentiment remains negative: Dominari has an average “Sell” rating, with Weiss Ratings maintaining a sell grade and Wall Street Zen downgrading the stock from hold to sell.

Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) CEO Anthony Hayes purchased 50,000 shares of the company's stock in a transaction dated Thursday, September 10th. The shares were acquired at an average price of $2.02 per share, for a total transaction of $101,000.00. Following the purchase, the chief executive officer directly owned 4,550,873 shares in the company, valued at approximately $9,192,763.46. The trade was a 1.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Dominari Price Performance

Shares of NASDAQ:DOMH opened at $2.18 on Monday. The company has a market capitalization of $52.84 million, a P/E ratio of -0.40 and a beta of 0.87. The firm's 50 day simple moving average is $2.56 and its two-hundred day simple moving average is $2.92. Dominari Holdings Inc. has a 1-year low of $1.91 and a 1-year high of $8.40.

Dominari (NASDAQ:DOMH - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.13. The business had revenue of $16.79 million during the quarter, compared to analyst estimates of $16.79 million. Dominari had a negative net margin of 51.61% and a negative return on equity of 235.37%.

Wall Street Analyst Weigh In

Several research firms have commented on DOMH. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dominari in a research note on Monday, July 6th. Wall Street Zen lowered Dominari from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Dominari has an average rating of "Sell".

Institutional Trading of Dominari

A number of large investors have recently made changes to their positions in the stock. Creek Drive Management Group LLC bought a new position in shares of Dominari in the fourth quarter worth about $1,861,000. Vanguard Group Inc. boosted its position in Dominari by 8.0% in the 3rd quarter. Vanguard Group Inc. now owns 345,896 shares of the company's stock valued at $2,452,000 after buying an additional 25,694 shares during the period. Two Sigma Investments LP purchased a new stake in Dominari in the 3rd quarter valued at about $771,000. Geode Capital Management LLC grew its stake in Dominari by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock worth $361,000 after acquiring an additional 1,866 shares in the last quarter. Finally, Millennium Management LLC bought a new position in Dominari in the 3rd quarter worth about $213,000. 42.48% of the stock is owned by hedge funds and other institutional investors.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.